As of June 30, 2023, POINT had approximately $434.8 million in cash, cash equivalents, and investments, which is anticipated to fund operations into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PNT:
- POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
- Point Biopharma Global Inc. (PNT) Q2 Earnings Cheat Sheet
- Point Biopharma, ITM expand global supply agreement for n.c.a. Lutetium-177
- ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
- Point Biopharma assumed with a Buy at Jefferies
